Clinical Trial Update: A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of patritumab deruxtecan (U3-1402) in metastatic breast cancer and locally advanced breast cancer has completed. The update notes the study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Patritumab Deruxtecan (U3-1402) (patritumab deruxtecan)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 2 | Status: COMPLETED